GSTM1 and anemia (phenotype): Briefly, two studies in patients with CKD demonstrated an increase in mean Hb concentration after 12 months of intravenous 1,25(OH)2D administration by 1.0 mg/dL [15] and 1.2 mg/dL [16], and therefore improved control of anemia with reduced need for EPO.